Author(s):
Nandani Kewat, Hemshailabh Shriwas, Anish Chandy
Email(s):
anishpharma@gmail.com
DOI:
10.52711/0975-4377.2026.00007 
Address:
Nandani Kewat1, Hemshailabh Shriwas1, Anish Chandy2*
1Students, Pharmaceutics Department, Chouksey School of Pharmacy, CEC, Bilaspur, CG.
2Associate Professor, Pharmaceutics Department, Chouksey School of Pharmacy, CEC, Bilaspur, CG.
*Corresponding Author
Published In:
Volume - 18,
Issue - 1,
Year - 2026
ABSTRACT:
Glibenclamide (Glyburide) is a powerful oral antidiabetic agent and orally active second-generation sulphonyl urea drug used in the reduction of blood sugar of patients with type of diabetes mellitus (NIDDM). Glibenclamide is short half-life of 4-6 hours. Development and evaluation of aquasomes of Glibenclamide for controlled/sustained drug release is the objective of this study. The aquasomes were prepared using calcium phosphate co ceramic with polyhydroxy oligomers sucrose/trehalose/lactose/cellobiose with 1:1 ,1:1.5 or 1:2 ratios. The prepared aquasomes were analysed for particle size, shape and FTIR study, % drug entrapment efficiency, zeta potential, in - vitro drug release studies. The percentages of drug entrapment efficiency and drug loading for the various aquasome formulations (F-1 to F-12) and they were found to be 79.8+-0.03, to 93.0+-0.05% and 7.1+-0.03% to 7.8+-0.03. It was found that the entrapment efficiency and drug loading was high for the lactose-coated Glibenclamide aquasomes of 1:2 core-to-core ratio formulation (F-12). By performing in vitro drug release study it was observed that the drug release of Glibenclamide from all the formulations was zero order kinetics. Stability studies for one month revealed that the formulations were stable till 400C at relative humidity of 75%. This outcome from release profiling strongly recommends that developed Glibenclamide loaded aquasomes can be useful delivery carrier to deliver drug in controlled release manner which is a prime requirement for the treatment of type II Diabetes mellitus (NIDDM).
Cite this article:
Nandani Kewat, Hemshailabh Shriwas, Anish Chandy. Formulation and Characterization of Drug Loaded Aquasomes for Effective Treatment of Type 2 Diabetes. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(1):39-6. doi: 10.52711/0975-4377.2026.00007
Cite(Electronic):
Nandani Kewat, Hemshailabh Shriwas, Anish Chandy. Formulation and Characterization of Drug Loaded Aquasomes for Effective Treatment of Type 2 Diabetes. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(1):39-6. doi: 10.52711/0975-4377.2026.00007 Available on: https://rjpdft.com/AbstractView.aspx?PID=2026-18-1-7
REFERENCES:
1. Govender, T., et al., PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water-soluble drug. Journal of Controlled Release. 1999. 57(2): 171-185.
2. Ofokansi, K., et al., Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2010. 76(1): 1-9.
3. Choi, C., S.Y. Chae, and J.-W. Nah, Thermosensitive poly(Nisopropylacrylamide)-b-poly(ε-caprolactone) nanoparticles for efficient drug delivery system. Polymer. 2006. 47(13): 4571- 4580
4. Scholes, P.D., et al., The preparation of sub200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery. Journal of Controlled Release. 1993. 25(1): 145-153.
5. Patri, A.K., J.F. Kukowska-Latallo, and J.R. Baker, Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Advanced Drug Delivery Reviews. 2005. 57(15): 2203-2214.
6. Rothenfluh, D.A., et al., Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nature Materials. 2008. 7(3): 248-254.
7. Devarakonda, B., et al., Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. International Journal of Pharmaceutics. 2005. 304(1): 193-209.
8. Merisko-Liversidge, E., G.G. Liversidge, and E.R. Cooper, Nanosizing: a formulation approach for poorly-water-soluble compounds. European Journal of Pharmaceutical Sciences. 2003. 18(2): p. 113-120.
9. Luo, Z. and J. Jiang, pH-sensitive drug loading/releasing in amphiphilic copolymer PAE–PEG: Integrating molecular dynamics and dissipative particle dynamics simulations. Journal of Controlled Release. 2012. 162(1): 185-193.
10. Kulkarni S, Prabhakar B, Shende P. Aquasomes: advanced vesicular-based nanocarrier systems. Curr Pharm Des. 2022; 28:2404–2414. doi:10.2174/1381612828666220728112741
11. Ramalingam PS, Balakrishnan P, Rajendran S, et al. Identification of dietary bioflavonoids as potential inhibitors against KRAS G12D mutant—novel insights from computer-aided drug discovery. Curr Issues Mol Biol. 2023; 45:2136–2156. doi:10.3390/cimb45030137
12. Banerjee S, Sen KK. Aquasomes: a novel nanoparticulate drug carrier. J Drug Deliv Sci Technol. 2018; 43:446–452. doi: 10.1016/j.jddst.2017.11.011
13. Hirani K, Sundheim B, Blaschke M, Lemos JR, Mittal R. A global call to action: strengthening strategies to combat dysglycemia and improve public health outcomes. Frontiers in Public Health. 2025 May 30; 13:1597128.
14. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus–conventional therapies and future perspectives in innovative treatment. Biochemistry and Biophysics Reports. 2025 Jun 1; 42:102037.
15. Luzi L, Pozza G. Glibenclamide: an old drug with a novel mechanism of action? Acta Diabetologica. 1997 Dec; 34(4):239-44.
16. Sanz D, Claramunt RM, Alkorta I, Sánchez‐Sanz G, Elguero J. The structure of glibenclamide in the solid state. Magnetic Resonance in Chemistry. 2012 Mar; 50(3):246-55.
17. Kaminski L, Degenhardt M, Ermer J, Feußner C, Höwer-Fritzen H, Link P, Renger B, Tegtmeier M, Wätzig H. Efficient and economic HPLC performance qualification. Journal of Pharmaceutical and Biomedical Analysis. 2010 Feb 5;51(3):557-64.
18. Punugoti RA, Jupally VR. Design and validation of simple UV spectrophotometric method for the assay of glibenclamide in in tablet dosage form. International Journal of Pharmaceutical, Biological and Chemical Sciences. 2013; 2(4): 52-6.